Collectively, this highlights the critical aspects spanning from tumor biology, treatment history, timing and method of tissue sampling and handling, to diagnostic antibody selection, processing and scoring, as determinants and caveats for successful implementation of PDL-1 as a clinical biomarker. This evidence concerns the gene CD274 and neoplasm.